MIF and neoplasm: Taken as a whole, our results in conjunction with accumulated evidence from other cancer studies, suggest that selective MIF inactivation upon treatment with ISO-66 restores the lytic ability of tumor-reactive CTLs and NK cells, which become immunocompetent.